CAS 1051375-19-9

Dolutegravir sodium salt

Description:

Dolutegravir sodium salt is an antiretroviral medication primarily used in the treatment of HIV infection. It belongs to the class of integrase strand transfer inhibitors (INSTIs), which work by blocking the integrase enzyme, thereby preventing the integration of viral DNA into the host genome. This compound is characterized by its high potency and favorable pharmacokinetic profile, allowing for once-daily dosing. Dolutegravir is known for its low potential for drug-drug interactions and is often used in combination with other antiretroviral agents to enhance efficacy and reduce the risk of resistance. The sodium salt form enhances its solubility and stability, making it suitable for oral administration. In clinical settings, it has demonstrated a strong ability to suppress viral load and improve immune function in patients. Additionally, Dolutegravir has a favorable safety profile, with a low incidence of adverse effects, although monitoring for potential side effects, such as hypersensitivity reactions and weight gain, is recommended. Overall, Dolutegravir sodium salt represents a significant advancement in HIV treatment regimens.

Formula: C₂₀H₁₈F₂N₃NaO₅

InChI: InChI=1S/C20H19F2N3O5.Na/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22;/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28);/t10-,15+;/m1./s1

InChI key: InChIKey=FOZLBAIXQATFFW-VSLILLSYSA-N

SMILES: O=C1C=2N(C[C@]3(N1[C@H](C)CCO3)[H])C=C(C(NCC4=C(F)C=C(F)C=C4)=O)C(=O)C2O.[Na]

Synonyms:

• 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, sodium salt
• 2H-Pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, sodium salt (1:1), (4R,12aS)-
• Dolutegravir sodium
• Gsk 1349572A
• Dolutegravir sodium salt
• GSK1349572 sodiuM salt
• Dolutegravir sodium(GSK1349572)
• Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate
• (4r,12as)-9-[(2,4-difluorophenyl)methylcarbamoyl]-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2h-pyrido[5,6]pyrazino[2,6-b][1,3]oxazin-7-olate
• Dolutegravir SodiuM ( API)
• Dolutegravi Sodium
• Dolutegravir Sodium (GSK-1349572A)
• (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide sodium salt (1:1)
• (4R,12AS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyri
• 158439

Alendronate Sodium Hydrate

CAS: 1051375-19-9

Alendronate Sodium Hydrate

Formula: C₂₀H₁₈F₂N₃NaO₅

Purity: 99%

Molecular weight: 441.36

Ref: 54-PC109057

Dolutegravir Sodium

CAS: 1051375-19-9

Formula: C₂₀H₁₈F₂N₃NaO₅

Purity: 99%

Color and Shape: Solid

Molecular weight: 441.3606

Ref: IN-DA00HAL5

Dolutegravir Sodium Salt

CAS: 1051375-19-9

Formula: C₂₀H₁₈F₂N₃O₅·Na

Color and Shape: Pale Yellow Solid

Molecular weight: 418.38 22.99

Ref: 4Z-D-093025

Dolutegravir sodium

CAS: 1051375-19-9

Dolutegravir sodium

Formula: C₂₀H₁₈F₂N₃NaO₅

Purity: ≥98%

Color and Shape: Solid

Molecular weight: 441.36

Ref: 54-BUP12449

Dolutegravir Sodium

CAS: 1051375-19-9

Color and Shape: Light Yellow

Ref: 86-MM3758.00

Dolutegravir sodium

CAS: 1051375-19-9

Dolutegravir sodium (GSK-1349572A) salt(DTG; GSK1349572) is an HIV integrase inhibitor(IC50: 2.7 nM), modest activity against raltegravir-resistant signature

Formula: C₂₀H₁₈F₂N₃NaO₅

Purity: 98% - 99.46%

Color and Shape: Solid

Molecular weight: 441.36

Ref: TM-T2329

Dolutegravir Sodium

CAS: 1051375-19-9

Formula: C₂₀H₁₈F₂N₃O₅Na

Molecular weight: 418.4 : 23.0

Ref: ST-EA-CP-D24000

Dolutegravir Sodium

CAS: 1051375-19-9

Applications Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011)

Formula: C₂₀H₁₈F₂N₃O₅·Na

Color and Shape: Neat

Molecular weight: 441.36

Ref: TR-D528805

Dolutegravir sodium

CAS: 1051375-19-9

Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate

Formula: C₂₀H₁₈F₂N₃NaO₅

Purity: 99%

Molecular weight: 441.36

Ref: IN-DG303670

Dolutegravir Sodium-d4

Controlled Product

CAS: 1051375-19-9

Formula: C₂₀H₁₄D₄F₂N₃O₅·Na

Color and Shape: Neat

Molecular weight: 447.398

Ref: TR-D528807

Dolutegravir Sodium Salt-D4

Controlled Product

CAS: 1051375-19-9

Formula: C₂₀D₄H₁₄F₂N₃NaO₅

Color and Shape: Neat

Molecular weight: 445.385

Ref: TR-D528806

Dolutegravir sodium

CAS: 1051375-19-9

Dolutegravir sodium is an HIV integrase strand transfer inhibitor with action on HIV integrase to block viral replication and is used for treating HIV/AIDS in combination with other antiretroviral medications.

Formula: C₂₀H₁₉F₂N₃NaO₅

Purity: (Hplc) 98.0 To 102.0%

Color and Shape: Powder

Molecular weight: 442.40 g/mol

Ref: 3D-BSB37519